Becton Dickinson and Co (BDX) Shares Sold by US Bancorp DE

US Bancorp DE decreased its stake in Becton Dickinson and Co (NYSE:BDX) by 2.0% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 104,836 shares of the medical instruments supplier’s stock after selling 2,137 shares during the period. US Bancorp DE’s holdings in Becton Dickinson and were worth $26,181,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Harvest Group Wealth Management LLC purchased a new position in Becton Dickinson and during the 1st quarter worth $25,000. Pinnacle Financial Partners Inc. purchased a new position in Becton Dickinson and during the 1st quarter worth $29,000. RPG Investment Advisory LLC purchased a new position in Becton Dickinson and during the 1st quarter worth $32,000. Nalls Sherbakoff Group LLC purchased a new position in Becton Dickinson and during the 4th quarter worth $34,000. Finally, Aspire Private Capital LLC purchased a new position in Becton Dickinson and during the 4th quarter worth $39,000. Institutional investors and hedge funds own 84.03% of the company’s stock.

Shares of BDX traded up $2.08 during trading hours on Friday, reaching $236.08. The company had a trading volume of 20,613 shares, compared to its average volume of 1,274,750. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $63.11 billion, a PE ratio of 21.58, a P/E/G ratio of 1.75 and a beta of 1.16. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business’s revenue was down .6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.65 EPS. On average, research analysts anticipate that Becton Dickinson and Co will post 11.7 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 annualized dividend and a yield of 1.30%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the firm’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the completion of the transaction, the chief executive officer now directly owns 227,250 shares in the company, valued at approximately $56,903,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 8,309 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $255.13, for a total transaction of $2,119,875.17. Following the transaction, the chief executive officer now owns 222,785 shares of the company’s stock, valued at $56,839,137.05. The disclosure for this sale can be found here. Insiders have sold a total of 47,469 shares of company stock valued at $11,675,851 over the last 90 days. 0.12% of the stock is currently owned by insiders.

A number of equities analysts have commented on the stock. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. Piper Jaffray Companies upped their price objective on shares of Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 5th. UBS Group cut their price objective on shares of Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, May 10th. Wells Fargo & Co cut their price objective on shares of Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research report on Monday, May 13th. Finally, BMO Capital Markets cut their price target on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a report on Friday, May 10th. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $255.31.

TRADEMARK VIOLATION WARNING: This report was reported by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thestockobserver.com/2019/05/24/becton-dickinson-and-co-bdx-shares-sold-by-us-bancorp-de.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: How to execute a trade ex-dividend strategy?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.